Please click on a question below to view its answer. If you don't find the information you are looking for please submit your question by clicking here.
OGF can cause a stomach contraction soon after injection. To avoid this, it is advisable to eat or
drink immediately prior to the injection.
Some patients experience paresthesia (tingling in nose/lips). This passes after a few seconds.
No other side effects have been reported.
Trials in animals have confirmed that Gemzar in far more effective in treating pancreatic cancer
when combined with OGF. Human trials have not yet been performed, however some physicians have
already combined the two treatments. In this case, the Gemzar is given in hospital periodically, and
the OGF is self administered at home daily.
A story of a patient who successfully combined the two treatments can be found on the User's Stories
page.
Yes, we posted the published results on our site in march 2010 - on the OGF Clinical Research page -
here is the link
http://www.ldnscience.org/opioid-growth-factor-ogf/published-research-about-ogf/clinical-trials
OGF is not FDA approved. However it is permitted for compounding pharmacies to prepare it based on a
physician's request. At the moment we are unaware of US pharmacies preparing it due to the large
quantity of OGF their suppliers ask them to purchase. Most pharmacies are unable to afford such a
large outlay.
There are two sources of OGF outside the US where US patients get OGF from. Please contact us using
the "Contact Us" form and we can send you the information.
Research has shown that myeloma cell growth is controlled by OGF receptors, thus making myeloma a
potential candidate for the use of OGF. No formal trials have yet been conducted.
Painkillers are compatible with OGF treatment. Opiate based painkillers work by targeting the mu
receptor, whilst OGF targets the zeta (OGF) receptor. They do not clash.
There is no harm in taking OGF immediately, however it will take a few hours (depending on
individual metabolism) for the LDN to clear the receptors, making way for the OGF to bind there.
Please see our video animation explaining how LDN works which should clarify this in more detail. It
can be viewed on our homepage.
OGF is a growth factor regulator, and works in all cells, cancerous or non-cancerous.
It is different that the growth factor inhibitors targeting specific aberrations present in tumors.
The dose used in clinical trials has been discussed in the OGF section of this website. It has
typically been 50mcg/k.g. subcutaneously twice daily, or 250mcg/k.g. intravenously (diluted in
saline), once or twice weekly.
Please refer to the interview with Moshe Rogosnitzky on this site where other doses being used by
doctors are discussed.
The OGF-OGFr pathway of regulating cell proliferation has been uncovered so far in over 20 cancers.
These have included the majority of cancers of the digestive tract. Cholangiocarcinoma has not yet
specifically been examined, however so far no cells have been found to be missing the OGF-OGFr cell
proliferation pathway.
It is reasonable to assume that cholangiocarcinoma could be a candidate for OGF treatment, and
hopefully this question will be addressed in clinical trials in the future.
OGF has been researched in bladder cancer cell lines where it has been found to be effective. This
research has been performed at Penn State University in Dr. Ian S. Zagon's laboratory but has not
yet been published.
Research has so far examined the use of one of the other, and not both at the same time. Since
LDN antagonizes the interaction between OGF and the OGF receptor, they should not be combined.
However, some physicians have tried giving LDN at times far away from OGF, so that the LDN has been
excreted by the time the OGF has been administered. Their reasoning is that since LDN also increases
OGF receptor numbers and sensitivity, the spread-out combination may make OGF more effective. This
question remains to be resolved in trials, however none are planned at the moment.
OGF must be administered via injection. In clinical trials it has been used both intravenously (into
a vein) and subcutaneously (under the skin). For home use the subcutaneous route is considered more
practical and is the method used by most patients.
As OGF is a molecule also naturally produced in the body, it does not cause toxic effects. However,
since it is a naturally-occurring opiate, administering it incorrectly can cause side effects like
those experienced when administering opiates via injection. When OGF is given intravenously, it must
be well-diluted and administered slowly in order to prevent hypotension (low blood pressure). Rapid
administration can also cause paresthesia – a tingling sensation around the nose and lips, which
usually resolves within minutes. It should also be administered after the patient has eaten or
drunk, in order to avoid a sometimes painful stomach contraction which sometimes occurs. When it is
administered via subcutaneous injection, side effects are not usually encountered, as the absorption
is slower. However it is still advised to eat or drink prior to the injection.
Chemotherapy is usually a cyto-toxic agent (cyto=cancer). OGF is considered a cyto-static agent and
not a cyto-toxic agent. OGF acts to regulate cell division rate thus slowing down the growth of
cancer cells. It follows logically that it would be beneficial to combine it with chemotherapy, thus
slowing down cancer cell growth and making it easier for the chemotherapy to have its toxic effects
on the cancer. So far clinical trials have been carried out in pancreatic cancer combining OGF with
Gemzar® (Gemcitabine). The combination is turning out to be more effective than either drug alone.
Some physicians are combining OGF with other chemotherapy or biological drugs, with claimed success.
However clinical trials to verify this have yet to be performed.
OGF has been used in clinical trials in Europe in some autoimmune disease such as Multiple
Sclerosis, Behcet’s Disease, Optic neuritis and Uveitis. Preclinical research is showing that it
may also have a useful role in treating neurodegenerative diseases such as Parkinson’s and ALS
(motor neurone disease). Further clinical trials are called for.
|
Questions & Answers
